I now have all the key information needed. Let me compile the comprehensive answer.
Types of Pulmonary Hypertension
Definition
Pulmonary hypertension (PH) is defined hemodynamically as a mean pulmonary artery pressure (mPAP) > 20 mmHg at rest on right heart catheterization (RHC), updated from the older threshold of >25 mmHg at the 6th World Symposium on Pulmonary Hypertension (WSPH, 2018). - Harrison's Principles of Internal Medicine, 22nd Ed.
WHO/WSPH Clinical Classification (6th WSPH, 2018)
The current classification divides PH into 5 groups based on underlying etiology and pathophysiological mechanism. Assignment to the correct group is essential because only Groups 1 and 4 have specific, proven targeted therapies. - Murray & Nadel's Textbook of Respiratory Medicine
Group 1 - Pulmonary Arterial Hypertension (PAH)
Mechanism: Precapillary - characterized by marked pulmonary arterial remodeling (intimal fibrosis, medial hypertrophy, plexiform lesions). Hemodynamic criteria: mPAP >20 mmHg + PVR >2.0 Wood Units + PAWP ≤15 mmHg. - Harrison's 22E
| Sub-type | Notes |
|---|
| 1.1 Idiopathic PAH (IPAH) | Most common; mean age at diagnosis now 54-68 years; female predominance (~3:1) |
| 1.2 Heritable PAH | Most commonly BMPR2 mutation; younger at diagnosis, more severe |
| 1.3 Drug- and toxin-induced | Anorexigens (fenfluramine), methamphetamine, dasatinib |
| 1.4 Associated PAH | Connective tissue disease, HIV, portal hypertension (portopulmonary), congenital heart disease, schistosomiasis |
| 1.5 PAH long-term responders to CCBs | Acute vasoreactivity test positive subset |
| 1.6 PAH with PVOD/PCH features | Pulmonary veno-occlusive disease / pulmonary capillary hemangiomatosis overlap |
| 1.7 Persistent PH of the newborn | |
Epidemiology: PAH is rare (~15 cases per million adults) but disproportionately affects young, otherwise healthy women. In resource-rich countries, PAH accounts for only ~3% of pulmonary vascular disease.
Group 2 - PH Due to Left Heart Disease (Most Common Overall)
Mechanism: Postcapillary - elevated pulmonary venous pressure transmitted backward from the left heart. Left heart disease and lung disease are the most common causes of PH in developed countries. In one large RHC cohort, 46% of patients had Group 2 vs. only 16% with precapillary PAH. - Fuster & Hurst's The Heart, 15th Ed.
| Sub-type |
|---|
| 2.1 HF with preserved ejection fraction (HFpEF) - increasingly the leading cause |
| 2.2 HF with reduced/mildly reduced ejection fraction (HFrEF) |
| 2.3 Valvular heart disease |
| 2.4 Congenital/acquired cardiovascular conditions causing postcapillary PH |
Group 3 - PH Due to Lung Disease and/or Hypoxia
Mechanism: Precapillary - hypoxic pulmonary vasoconstriction + parenchymal/vascular remodeling. Second most common cause of PH in developed countries.
| Sub-type |
|---|
| 3.1 Obstructive lung disease (COPD) - ~1/3 of end-stage COPD patients referred for transplant have PH |
| 3.2 Restrictive lung disease (ILD, pulmonary fibrosis) |
| 3.3 Mixed obstructive/restrictive pattern |
| 3.4 Hypoventilation syndromes (OSA, obesity-hypoventilation/Pickwickian) - usually mild PH |
| 3.5 Hypoxia without lung disease (e.g. high altitude) |
| 3.6 Developmental lung disorders |
Group 4 - PH Due to Pulmonary Artery Obstructions (CTEPH)
Mechanism: Mechanical obstruction + secondary vascular remodeling. Occurs in ~3-4% of all patients after acute pulmonary embolism. Uniquely potentially curable with pulmonary thromboendarterectomy (PTE). About 25% of CTEPH patients have no documented prior PE. - Murray & Nadel's, Fuster & Hurst's
| Sub-type |
|---|
| 4.1 Chronic thromboembolic PH (CTEPH) |
| 4.2 Other pulmonary artery obstructions (sarcomas, other malignant/non-malignant tumors, hydatid cysts) |
CTEPH can be clinically identical to IPAH - distinguishing them is essential because treatment differs fundamentally.
Group 5 - PH with Unclear and/or Multifactorial Mechanisms
A heterogeneous group where the mechanism causing PH is not clearly established or involves multiple contributing pathways. - Harrison's 22E
| Sub-type | Examples |
|---|
| 5.1 Hematological disorders | Chronic hemolytic anemia, myeloproliferative disorders |
| 5.2 Systemic disorders | Sarcoidosis, pulmonary Langerhans cell histiocytosis, neurofibromatosis type 1 |
| 5.3 Metabolic disorders | Glycogen storage disease, Gaucher disease, thyroid disorders |
| 5.4 Chronic renal failure (with or without hemodialysis) | |
| 5.5 Pulmonary tumor thrombotic microangiopathy | |
| 5.6 Fibrosing mediastinitis | |
Global Epidemiology by Group
The chart below (from Fuster & Hurst's The Heart, 15th Ed.) illustrates the striking difference in cause distribution between resource-rich and resource-limited settings:
In resource-rich areas: left heart disease (55%) and COPD (42%) dominate; PAH is only 3%.
In resource-limited areas: high altitude (24%), schistosomiasis (18%), and COPD (29%) are prominent; infectious/inflammatory disorders play a much larger role.
Key Hemodynamic Classification Points
| Hemodynamic Type | mPAP | PAWP | PVR | Associated Groups |
|---|
| Precapillary PH | >20 mmHg | ≤15 mmHg | >2 WU | Groups 1, 3, 4, 5 |
| Postcapillary PH | >20 mmHg | >15 mmHg | - | Group 2 |
| Combined pre+postcapillary | >20 mmHg | >15 mmHg | >2 WU | Group 2 (severe) |
Clinical Importance of Classification
- Groups 1 & 4 are the only groups with approved targeted therapies (prostacyclins, endothelin antagonists, PDE-5 inhibitors for Group 1; PTE surgery + riociguat for Group 4)
- Groups 2 & 3 are treated by managing the underlying left heart or lung disease; PAH-specific drugs are generally not indicated and may be harmful
- Group 5 has no specific treatments; management targets the underlying systemic condition
Sources: Harrison's Principles of Internal Medicine 22E; Fuster & Hurst's The Heart 15th Ed.; Murray & Nadel's Textbook of Respiratory Medicine